Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 01, 2024 16:15 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio Announces $25 Million Registered Direct Offering
April 25, 2024 19:15 ET
|
Belite Bio, Inc
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel...
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
March 22, 2024 08:00 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 11, 2024 22:28 ET
|
Belite Bio, Inc
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024 21:27 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
March 06, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
March 04, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...